Javascript must be enabled to continue!
Arm's Length Method for Comparing Rating Scales
View through CrossRef
Investors are being encouraged after the global crisis to reduce their dependence on the largest credit rating agencies for risk assessments of companies and securities. Comparing risk assessments from different sources rapidly becomes non-trivial when more than three credit rating agencies are involved. We propose a method for comparing rating scales, and hence constructing correspondence diagrams and tables, thereby treating the rating scales used by different agencies as objects of study. Scales are compared by looking at sets of ratings assigned to similar entities (in this case banks) with the assumption that the risk being measured by each credit rating agency is the same for a given rated entity at a given point in time. Two ratings assigned by two credit rating agencies may differ for two reasons: the two agencies have different opinions about the relative positioning of the rated entity (e.g., issuer or security) with respect to the universe of other rated entities; both agencies position the rated entity with respect to the universe of other rated entities in the same way, but they use different symbols to represent this position. Type 1 differences should disappear when a large number of ratings are considered. The existence of type 2 differences will require a mapping from one rating scale to another. Studying international bank ratings for a five-year period shows that there are type 2 differences for the largest credit rating agencies. A mechanism for constructing mappings between scales could lead to more competition with new credit rating agencies.
Title: Arm's Length Method for Comparing Rating Scales
Description:
Investors are being encouraged after the global crisis to reduce their dependence on the largest credit rating agencies for risk assessments of companies and securities.
Comparing risk assessments from different sources rapidly becomes non-trivial when more than three credit rating agencies are involved.
We propose a method for comparing rating scales, and hence constructing correspondence diagrams and tables, thereby treating the rating scales used by different agencies as objects of study.
Scales are compared by looking at sets of ratings assigned to similar entities (in this case banks) with the assumption that the risk being measured by each credit rating agency is the same for a given rated entity at a given point in time.
Two ratings assigned by two credit rating agencies may differ for two reasons: the two agencies have different opinions about the relative positioning of the rated entity (e.
g.
, issuer or security) with respect to the universe of other rated entities; both agencies position the rated entity with respect to the universe of other rated entities in the same way, but they use different symbols to represent this position.
Type 1 differences should disappear when a large number of ratings are considered.
The existence of type 2 differences will require a mapping from one rating scale to another.
Studying international bank ratings for a five-year period shows that there are type 2 differences for the largest credit rating agencies.
A mechanism for constructing mappings between scales could lead to more competition with new credit rating agencies.
Related Results
Safety and Efficacy of Atezolizumab in Ovarian Cancer
Safety and Efficacy of Atezolizumab in Ovarian Cancer
Abstract
Introduction
Although the efficacy of PD-L1 blockade has been evaluated in analyses that combine pharmacologically distinct antibodies, the specific efficacy and safety of...
Radioimmunotherapy with Yttrium-90-Ibritumomab Tiuxetan as Part of a Reduced Intensity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation in Patients with Advanced Non-Hodgkin Lymphoma: A Phase I/II Study.
Radioimmunotherapy with Yttrium-90-Ibritumomab Tiuxetan as Part of a Reduced Intensity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation in Patients with Advanced Non-Hodgkin Lymphoma: A Phase I/II Study.
Abstract
Allogeneic hematopoietic cell transplantation (HCT) using reduced intensity conditioning (RIC) regimens offers a potential curative therapy to patients with...
Efficacy of Painhunting Therapy for Event-Related Depression: A Randomized Controlled Trial with Crossover Replication
Efficacy of Painhunting Therapy for Event-Related Depression: A Randomized Controlled Trial with Crossover Replication
Abstract
Background
Depression affects an estimated 332 million people worldwide and is a leading cause of disability, with up ...
De-escalation of axillary surgery in breast cancer : patient experiences, arm morbidity, and health-related quality of life
De-escalation of axillary surgery in breast cancer : patient experiences, arm morbidity, and health-related quality of life
<p dir="ltr">In breast cancer surgery for node-positive disease, axillary staging surgery is typically performed alongside the tumour removal. Arm morbidity is a known conseq...
De-escalation of axillary surgery in breast cancer : patient experiences, arm morbidity, and health-related quality of life
De-escalation of axillary surgery in breast cancer : patient experiences, arm morbidity, and health-related quality of life
<p dir="ltr">In breast cancer surgery for node-positive disease, axillary staging surgery is typically performed alongside the tumour removal. Arm morbidity is a known conseq...
Differential Diagnosis of Neurogenic Thoracic Outlet Syndrome: A Review
Differential Diagnosis of Neurogenic Thoracic Outlet Syndrome: A Review
Abstract
Thoracic outlet syndrome (TOS) is a complex and often overlooked condition caused by the compression of neurovascular structures as they pass through the thoracic outlet. ...
Does motivational interviewing reduce health services use and mortality in heart failure patients? A secondary analysis of the MOTIVATE-HF trial
Does motivational interviewing reduce health services use and mortality in heart failure patients? A secondary analysis of the MOTIVATE-HF trial
Abstract
Funding Acknowledgements
Type of funding sources: Public Institution(s). Main funding source(s): Center of Excellence f...
Abstract LB-229: Treatment of advanced cancer patients with a newest poly-epitope peptide vaccine to the thymidylate synthase(TSPP): a phase Ib (TSPP/VAC1) trial
Abstract LB-229: Treatment of advanced cancer patients with a newest poly-epitope peptide vaccine to the thymidylate synthase(TSPP): a phase Ib (TSPP/VAC1) trial
Abstract
Background TSPP is a poly-epitope peptide vaccine to the thymidylate syntase (TS) an enzyme commonly over-expressed in replicating cancer cells and recogniz...

